Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Firefly has created an innovative platform for cancer treatment utilizing degrader antibody conjugates (DACs). This platform ensures precise and highly specific delivery of therapeutic payloads to target tissues. Headquartered in South San Francisco, Firefly is supported by a prominent syndicate that includes Versant Ventures, MPM BioCapital, Decheng, and Eli Lilly & Company, with Versant Ventures being the founding investor.

List your booth number for exhibitions, ask us